If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
109.50    0.00 (0.00%)
Bid:
107.00
Ask:
112.00
Spread: 5.00 (4.673%)
Market Cap: £14.77m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Awards under Long Term Incentive Plan

10 Jan 2013 07:01

RNS Number : 2205V
Revolymer PLC
10 January 2013
 



10th January 2013

Revolymer plc

("Revolymer" or "the Group")

Awards under Long Term Incentive Plan

 

Revolymer (AIM: REVO), the British polymer company developing patented products for a number of high value fast moving consumer goods ("FMCG") and industrial markets, announces the grant on 9 January 2013 of awards under the Revolymer plc Long Term Incentive Plan ("LTIP") to executive directors.

 

The LTIP was adopted by the board of directors of Revolymer plc (the "Board") on 29 June 2012 and its remuneration committee has approved the following grants to executive directors on 9 January 2013:

 

- To the CEO Roger Pettman a nil cost option over 281,690 ordinary shares

- To the CFO Robin Cridland a nil cost option over 253,521 ordinary shares

 

The vesting period of these grants is three years and they only become exercisable if challenging performance conditions are met; namely that 50% of the grant becomes exercisable if the weighted average ordinary share price in the 30 day period ending on the third anniversary of grant is 125p. Between weighted average ordinary share prices of 125p and 150p, vesting shall be pro-rata and on a straight line basis between 50% and 100%. Below 125p the grants are not exercisable and lapse in full.

The Board also requires the executive directors to maintain minimum interests (of at least 400,000 ordinary shares for Roger Pettman and 360,000 ordinary shares for Robin Cridland) before selling any ordinary shares that are the result of exercise, except that they may sell that number of ordinary shares that are required to satisfy any income tax and employee's national insurance liabilities arising at exercise. This requirement shall not apply on a change of control, or other transaction with substantially the same effect.

Ends

 

For further information please contact:

 

Revolymer plc

+44 (0) 1244 283 500

Roger Pettman

Rob Cridland

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Callum Stewart / Adam James (Corporate Finance)

Adam Pollock / Charles Leigh-Pemberton (Corporate Broking)

Citigate Dewe Rogerson

+44 (0)20 7638 9571

Simon Rigby / David Dible / Ginny Pulbrook

 

 

 

About Revolymer

Revolymer is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the FMCG markets. Revolymer's strategy is to generate significant and growing revenue streams by licensing its unique and proprietary technologies to manufacturers and marketers within the global high value FMCG industry. Current applications for the Group's technologies are in the coatings & adhesives, household products and personal care markets (together "Consumer Specialties") and the confectionery chewing gum and medicated chewing gum (together "Gum") markets.

 

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBLMTTMBBMTTJ
Date   Source Headline
18th Apr 20177:00 amRNSNotice of AGM and Posting of Annual Report
4th Apr 20177:00 amRNSPreliminary Results Announcement - Replacement
27th Mar 20177:00 amRNSFinal Results
1st Mar 20177:00 amRNSChange of Name to Itaconix plc
10th Feb 20177:00 amRNSHolding(s) in Company
1st Feb 20171:33 pmRNSTotal Voting Rights
27th Jan 201711:53 amRNSJoint development agreement with AkzoNobel
23rd Jan 20177:00 amRNSExclusive Supply & Marketing Agreement with Croda
9th Jan 20177:00 amRNSBlock listing Interim Review
3rd Jan 20177:00 amRNSChange of Adviser
30th Dec 20169:22 amRNSDirectorate Change
2nd Nov 20161:18 pmRNSDivestment of Nicotine Gum Business
14th Oct 20167:00 amRNSDirector/PDMR Shareholding
6th Oct 20167:00 amRNSDirector/PDMR Shareholding
30th Sep 20167:00 amRNSDirector/PDMR Shareholding
22nd Sep 20167:00 amRNSInterim Results
19th Sep 20167:00 amRNSDivestment of Nicotine Gum Business
13th Sep 201611:34 amRNSDirectorate Change
7th Sep 20167:00 amRNSFirst Commercial Sales of Itaconix® CHTT
1st Aug 201611:33 amRNSTotal Voting Rights
15th Jul 20168:04 amRNSHolding(s) in Company
11th Jul 20164:34 pmRNSHolding(s) in Company
11th Jul 20163:35 pmRNSBlock listing Interim Review
8th Jul 201611:55 amRNSResult of General Meeting
8th Jul 20167:00 amRNSSuccessful Application for Accelerated Whitewash
22nd Jun 20164:29 pmRNSPosting of Circular and Notice of General Meeting
21st Jun 20162:24 pmRNSResults of Placing
21st Jun 20167:00 amRNSAcquisition & Placing
20th Jun 20165:31 pmRNSAcquisition & Placing
19th May 20162:33 pmRNSResult of AGM
19th May 20167:00 amRNSAGM Statement
7th Apr 20167:00 amRNSNotice of AGM & Posting of Annual Report
1st Apr 20167:00 amRNSTotal Voting Rights
21st Mar 20167:00 amRNSFinal Results
16th Mar 20167:00 amRNSDirectorate Change
1st Mar 20168:41 amRNSTotal Voting Rights
25th Jan 20167:00 amRNSRenewed & Expanded Contract
11th Jan 20167:00 amRNSBlocklisting Interim Review
30th Nov 20155:21 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSTotal Voting Rights
30th Oct 201512:30 pmRNSTotal Voting Rights
21st Sep 20157:00 amRNSInterim Results
18th Sep 20157:00 amRNSDirectorate Change
7th Sep 201512:18 pmRNSTotal Voting Rights
2nd Sep 20157:00 amRNSBlocklisting Interim Review
1st Sep 20157:03 amRNSLicence with OCI Alabama LLC
15th Jun 201512:27 pmRNSHolding(s) in Company
3rd Jun 20157:00 amRNSGlobal licence signed with Solvay
20th May 201512:17 pmRNSResult of AGM
15th May 20151:21 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.